Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03871829 · ClinicalTrials.gov registry record · Phase 2
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
A Phase 2 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT03871829 is a Phase 2 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 88 participants.
The verdict
NCT03871829, a Phase 2 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy (rate of very good partial response \[VGPR\] or better as best response as defined by the International Myeloma Working Group \[IMWG\] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab to evaluate daratumumab retreatment.
Interventions
- DRUG Dexamethasone 40 mg
- DRUG Carfilzomib 20 mg/m^2
- DRUG Carfilzomib 70 mg/m^2
- DRUG Dara-SC 1800 mg
- DRUG Dexamethasone 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2019-05-31 |
| Est. Completion | 2023-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03871829
The ClinicalTrials.gov registry entry for NCT03871829 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone 40 mg is the first listed.
NCT03871829 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03871829 about?
NCT03871829 is a clinical study titled "Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab". The purpose of this study is to compare the efficacy (rate of very good partial response \[VGPR\] or better as best response as defined by the International Myeloma Working Group \[IMWG\] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the ...
What is the current status of trial NCT03871829?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2019-05-31. Estimated completion is 2023-01-10.
What interventions are being tested in trial NCT03871829?
The interventions under investigation include: Dexamethasone 40 mg (DRUG), Carfilzomib 20 mg/m^2 (DRUG), Carfilzomib 70 mg/m^2 (DRUG), Dara-SC 1800 mg (DRUG), Dexamethasone 20 mg (DRUG).
Who is sponsoring clinical trial NCT03871829?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.